Caption Management’s Pliant Therapeutics PLRX Stock Holding History

Caption Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-142,404	Closed	-$1.88M	–	1927
2024 Q4	$1.88M	Buy	+142,404	New	+$1.94M	0.02%	716
2024 Q1	–	Sell	-4,000	Closed	-$66K	–	1585
2023 Q4	$72.4K	Sell	4,000 -6,000	-60%	-$91.2K	﹤0.01%	1201
2023 Q3	$173K	Sell	10,000 -5,000	-33%	-$86.7K	﹤0.01%	1107
2023 Q2	$272K	Buy	+15,000	New	+$355K	﹤0.01%	906
2022 Q3	–	Sell	-11,000	Closed	-$88K	–	1771
2022 Q2	$88K	Buy	+11,000	New	+$70.4K	﹤0.01%	1302

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Caption Management's PLRX Position: Q1 2025 in Review

Caption Management sold out of Pliant Therapeutics (PLRX) in Q1 2025, closing a stake of 142,404 shares — an estimated $1.88M sold.

Caption Management first reported a position in PLRX in Q2 2022 and held it in 5 quarters. The position peaked at $1.88M in Q4 2024. 140 funds tracked by Wall St. Rank hold PLRX as of Q1 2025.

Caption Management reported no remaining Pliant Therapeutics position as of Q1 2025 after selling out during the quarter.
Caption Management sold 142,404 Pliant Therapeutics shares in Q1 2025, an estimated $1.88M.
Caption Management first reported a position in Pliant Therapeutics in Q2 2022 and held it in 5 quarters.
Caption Management's Pliant Therapeutics position peaked at $1.88M in Q4 2024.
140 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.